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Abstract
The potential for misuse, overdose, and chronic use has led researchers to look for other methods to decrease opioid consumption
in patients with acute and chronic pain states. The use of peripheral nerve blocks for surgery has gained increasing popularity as it
minimizes peripheral pain signals from the nociceptors of local tissue sustaining trauma and inflammation from surgery. The in-
dividualization of peripheral nerve blocks using adjuvant drugs has the potential to improve patient outcomes and reduce chronic
pain. The major limitations of peripheral nerve blocks are their limited duration of action and dose-dependent adverse effects.
Adjuvant drugs for peripheral nerve blocks show increasing potential as a solution for postoperative and chronic pain with their
synergistic effects to increase the duration of action and decrease the required dosage of local anesthetic. N-methyl-d-aspartate
(NMDA) receptor antagonists are a viable option for patients with opioid resistance and neuropathic pain due to their affinity to
the neurotransmitter glutamate, which is released when patients experience a noxious stimulus. Neostigmine is a cholinesterase
inhibitor that exerts its effect by competitively binding at the active site of acetylcholinesterase, which prevents the hydrolysis of
acetylcholine and subsequently retaining acetylcholine at the nerve terminal. Epinephrine, also known as adrenaline, can poten-
tially be used as an adjuvant to accelerate and prolong analgesic effects in digital nerve blocks. The theorized role of sodium bicar-
bonate in local anesthetic preparations is to increase the pH of the anesthetic. The resulting alkaline solution enables the anesthetic
to more readily exist in its un-ionized form, which more efficiently crosses lipid membranes of peripheral nerves. However, more
research is needed to show the efficacy of these adjuvants for nerve block prolongation as studies have been either mixed or have
small sample sizes.
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1. Context
Much attention has been brought to the use of opi-
oids for both acute and chronic pain in recent years. The
overuse of opioids for pain control has quadrupled the pre-
scription opioid deaths since 1999 (1). Although opioids
can be beneficial in controlling both acute and chronic
pain, the risk for dependence and overuse and numerous
side effects, including urinary retention, constipation, se-
dation, and other adverse effects, make the reliance on opi-
oids problematic (2, 3).
The pathophysiology of pain is multi-faceted and in-
volves components of peripheral and central nervous sys-
tems. As surgery is noted to be one of the most common
causes of chronic pain (22.5% of chronic pain), the transi-
tion from acute postoperative pain to chronic pain is the
focus of increasing research (1). Risk factors for the tran-
sition to chronic pain include younger age, female gen-
der, obesity, surgical technique, anesthetic type, and other
psychosocial factors (4). Other potential risk factors for
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chronic postoperative pain include genetic mutations in
COMT, OPRM1, GCH1, and others (1). The complexity of
chronic pain necessitates the individualization of genetic,
physiologic, and pharmacokinetic properties of nonopi-
oid pain treatments (5).
To decrease the morbidity and mortality due to opi-
oid use, peripheral nerve blocks are a promising answer
for acute pain and the transition to chronic pain man-
agement. The use of peripheral nerve blocks for surgery
has gained wide acceptance as it minimizes peripheral
pain signals from the nociceptors of local tissue sustaining
trauma and inflammation from surgery.
Peripheral nerve blocks have gained popularity as im-
provements in ultrasound technology enable safe, precise
techniques for local anesthetic injection. Despite improve-
ments in technique, peripheral nerve blocks are limited by
the duration of action (6). Continuous peripheral nerve
blocks (CPNB) provide long-term pain control via the tran-
scutaneous insertion of a catheter to the targeted nerve or
plexus through which local anesthetic can be infused (7).
Although CPNB provides an effective alternative for long-
term pain management, disadvantages of cost, difficulty
in insertion, and morbidity with catheter-associated infec-
tions and incidental dislodgement often outweigh its ad-
vantages (8). Due to these concerns, the use of an adjuvant
drug that extends the duration of action of the local anes-
thetic, which can be given in a single injection, is more fa-
vorable (9).
Dose-dependent adverse effects of peripheral nerve
blocks are reduced by adjuvant drugs but not entirely elim-
inated. Local anesthetic systemic toxicity (LAST) is one of
the most concerning adverse effects of peripheral nerve
blocks due to its systemic effects and long duration of
neurologic complications. Other adverse effects include
vascular puncture, hemorrhage, peripheral nerve injury,
and infection (10). Despite these complications, peripheral
nerve blocks are an effective alternative in postoperative
and chronic pain management, especially in patients who
are at high risk of opioid abuse or side effects of respira-
tory depression, urinary retention, and cognitive impair-
ment (2). NMDA antagonists, neostigmine, epinephrine,
and sodium bicarbonate play an important role as poten-
tial adjuvants for local anesthetics.
2. NMDA Antagonists
N-methyl-d-aspartate (NMDA) receptor antagonists are
a viable option for patients with opioid resistance and neu-
ropathic pain due to their affinity to the neurotransmitter
glutamate, which is released when patients experience a
noxious stimulus (11). There are several NMDA receptor an-
tagonists, each with unique levels of activity on a specific
receptor, with some such as ketamine having adverse cen-
tral nervous system (CNS) side effects that include halluci-
nations, confusion, a dreamlike state, and irrational behav-
ior (12). However, when utilized as an adjuvant with opi-
oids, ketamine can improve postoperative analgesia and
reduce total morphine consumption in patients undergo-
ing thoracic and abdominal surgeries (13, 14). Memantine,
amantadine, and dextromethorphan do not have the same
extensive list of adverse side effects compared to ketamine
and methadone, but they also do not show linear long-
term reduction of pain (15-17).
Although ketamine demonstrates more neurotoxicity
when used as an adjuvant for local anesthesia, it also di-
rectly inhibits Na+ channels where action potentials and
pain are initially created and maintained (4). In patients
with chronic regional pain syndrome (CRPS), ketamine,
when administered with a local anesthetic, demonstrate
sympatholytic traits against heat allodynia without ad-
verse side effects in the CNS when injected at 0.5 mg/kg (18).
While these NMDA receptors collectively prevent the
development of opioid tolerance, reduce pain scores, and
decrease pain medication consumption, it is understood
that more randomized clinical trials must be done to iso-
late NMDA’s physiological activation from its pathologi-
cal activation to minimize or eliminate CNS adverse ef-
fects on patients (19). Furthermore, additional studies
must be done to pinpoint the exact concentration for
these adjuvants to be effective in managing pain across
the board (20). Caution must be practiced when admin-
istering local anesthesia in pediatric patients due to the
risk of compartment syndrome, inhibition of motor func-
tions, and an increase in plasma levels (21). For safety, ad-
juvants like epinephrine, clonidine, and ketamine with-
out preservatives should be administered because the po-
tential of adverse side effects associated with these drugs
are low in children (21). Furthermore, location tech-
niques such as electrocardiogram guidance, stimulating
catheters, and ultrasonography should be utilized when
placing catheters and administering blockade in children
to assure children’s comfort (21).
2.1. Neostigmine
Neostigmine is a cholinesterase inhibitor that in-
creases acetylcholine levels at nerve terminals (22). It ex-
erts this effect by competitively binding at the active site
of acetylcholinesterase, which prevents the hydrolysis of
acetylcholine and subsequently retaining acetylcholine at
the nerve terminal (23). Cholinesterase inhibitors are com-
monly used in anesthesia to reverse the effects of nonde-
polarizing muscle relaxants, which competitively inhibit
acetylcholine receptors at the motor endplate. The in-
creased level of acetylcholine in the synaptic cleft com-
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petes for the binding of acetylcholine receptors and facil-
itates the degradation of the muscle relaxant. With newer,
shorter-acting muscle relaxants and the development of
specific reversal agents such as sugammadex for rocuro-
nium and vecuronium, however, cholinesterase inhibitors
have become less common in anesthesia in recent years
(22). The potential of cholinesterase inhibitors as adju-
vants for local anesthetics has yet to be fully determined.
It is thought that the potential of neostigmine as an
adjuvant is not through its action on endplates contain-
ing nicotinic receptors but through its action to increase
acetylcholine at muscarinic junctions of peripheral nerves
(24). Cholinesterase inhibitors activate intrinsic ascend-
ing and descending cholinergic pathways to exhibit a dose-
dependent effect (25). The use of neostigmine as a cen-
tral nerve anesthetic and adjuvant has been shown to be
effective but of limited use. As a postoperative analgesic,
neostigmine has been shown to be an effective intrathe-
cal alternative to opioids following lower limb orthope-
dic surgeries (25, 26). Activation of the parasympathetic
nervous system produces numerous side effects, however,
such as nausea, vomiting, diarrhea, and diaphoresis, so the
use of neostigmine as an intrathecal analgesic is limited
(23). As an adjuvant for epidural anesthesia, it showed ef-
ficacy at postoperative analgesia with minimal risk of nau-
sea and vomiting, but it increased the risk of sedation (27,
28). Due to its numerous side effects, it has limited use as a
centrally acting agent.
The use of neostigmine in peripheral nerve blocks has
shown mixed results in studies. Bone et al. found that
500 mcg of neostigmine used as an adjuvant to 500 mg of
mepivacaine in an axillary brachial plexus block resulted
in significantly lower pain ratings and decreased the use
of analgesics in the first 24 hours postoperatively com-
pared to placebo with no incidence of adverse effects (29).
Two other studies, however, showed no improvement in
postoperative analgesia (30, 31). Van Elstraete et al. found
that 500 mcg of neostigmine as an adjuvant to an axil-
lary brachial plexus block consisting of 450 mg of 1.5% li-
docaine and 5 mcg of epinephrine demonstrated no sig-
nificant difference in duration of analgesia, the need for
supplemental analgesia, or in pain ratings compared to
placebo. Side effects were not significantly different in the
experimental group compared to control (30). Bouaziz et
al. compared the use of 500 mcg of neostigmine as an ad-
juvant to mepivacaine in axillary plexus block through in-
jection of neostigmine either subcutaneously or directly
in the block compared to placebo. They found no signif-
icant difference in duration of the sensory block between
the three groups and a slight decrease in duration of motor
block in the subcutaneous neostigmine group compared
to the other two groups (P = 0.045). In addition, they found
significant gastrointestinal side effects in 30% of patients
in both neostigmine groups, with no side effects in the
placebo group (31). The use of neostigmine as an adjuvant
drug for peripheral nerve blocks is not recommended at
this time due to limited evidence of an increase in the du-
ration of postoperative analgesia and a significant increase
in gastrointestinal side effects (32).
2.2. Epinephrine
Epinephrine, also known as adrenaline, can potentially
be used as a local adjuvant to nerve blocks to accelerate and
prolong analgesic effects in neuraxial and peripheral nerve
blocks (33, 34). However, epinephrine causes vasoconstric-
tion and is often taught to healthcare professionals to not
be used in digital nerve blocks (DNB) due to the theoret-
ical risk of digital ischemia and necrosis (33). There is an
increased concern when handling patients with compro-
mised circulation in diseases such as peripheral vascular
disease (PVD) (33). However, epinephrine is often paired
as an adjunct drug to increase the efficiency of additional
nerve blocks such as lidocaine, although effects and mech-
anisms are not always clear (35-37).
In a 2015 systematic review looking at 39 studies, re-
searchers aimed to identify the safety of epinephrine in
healthy individuals and those with poor peripheral circu-
lation at a concentration of 1: 100,000 - 200,000 (33). Of the
studies examined, one identified complication in healthy
individuals, which included hypertensive crisis and infec-
tion (38). However, these complications did not occur at
an increased rate compared to the control group, who did
not receive epinephrine (38). No complications were re-
ported in thousands of DNBs (33). The review concluded
that not only was epinephrine safe for healthy individuals
but that it also accelerated and prolonged anesthesia and
analgesia, decreasing the need for additional local injec-
tions (33). Unfortunately, those with poor peripheral cir-
culation are often excluded from research involving DNBs
with epinephrine. Therefore the overall evidence is lack-
ing (33). However, in those studies that have included DNBs
in individuals with poor peripheral circulation, no compli-
cations have been reported (33). If ischemia does appear
to occur during the use of epinephrine with DNB, phento-
lamine can be used to reverse the effects (33).
Additionally, epinephrine can be combined as an
adjunct with another peripheral nerve block for in-
creased effectiveness (35-37). For example, the addition
of epinephrine to tetrodotoxin (TTX) plus chemical per-
meation enhancers (CPEs) greatly increases the duration
of sciatic nerve block in rats compared to any combi-
nation of two of the nerve blocks alone (35). The use of
epinephrine reduces the risk of systemic adverse reac-
tions, including mortality associated with TTX (35). This
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is believed to potentially be due to the vasoconstriction
effects of epinephrine causing retention of local drug
concentration, restricting systemic drug distribution (35).
Similar results have been found with the use of
epinephrine with lidocaine. Multiple studies have found
that the use of epinephrine increases the amplitude and
duration of analgesic effects of lidocaine as a peripheral
nerve block (36, 37). In rats, epinephrine can prolong the
effects of lidocaine in the sciatic nerve by a magnitude of
4-fold (36). Similarly, epinephrine and lidocaine combi-
nations have been used in horses with forefoot lameness
to determine safety and efficiency (37). A dilution of 1:
200,000 epinephrine with 1% lidocaine had increased ef-
ficacy and duration as a PNB compared to the 1 and 2% li-
docaine treatments alone with no adverse reactions (37).
In conclusion, epinephrine is a safe adjunct in peripheral
nerve blocks that can increase the amplitude and dura-
tion of analgesic effects for healthy individuals and those
with compromised circulation at a dilution of 1: 100,000 -
200,000.
2.3. Sodium Bicarbonate
The theorized role of sodium bicarbonate in local anes-
thetic preparations is to increase the pH of the anesthetic.
The resulting alkaline solution enables the anesthetic to
more readily exist in its un-ionized form. The un-ionized
anesthetic more efficiently crosses lipid membranes of pe-
ripheral nerves, which theoretically increases the effects of
the nerve blockade and results in a more rapid onset of ac-
tion (32). The amount of sodium bicarbonate needed to
produce an effect is variable due to differences in solution
pH between individual anesthetics and between manufac-
turers. For example, mepivacaine and lidocaine are two
anesthetics that will readily alkalinize with sodium bicar-
bonate and can be used with minimal risk of adverse ef-
fects. However, with some anesthetic solutions, such as
bupivacaine or ropivacaine, sodium bicarbonate must be
used in much smaller quantities for this purpose because
the anesthetic will more readily precipitate into an insol-
uble base with even slight increases in pH (39). Because
the extent of pH increase remains unknown, the potential
of sodium bicarbonate as an adjuvant to peripheral nerve
blocks has yet to be fully determined.
Several studies have investigated the use of bicarbon-
ate in peripheral nerve blocks, but the results are incon-
sistent. In rat models, Yung et al. found that adding
sodium bicarbonate to chloroprocaine shortened the on-
set of action but decreased the duration of the blockade,
and adding both bicarbonate and epinephrine to chloro-
procaine shortened the onset of action and increased the
duration of blockade (40). Human studies have shown
conflicting results, and clinical significance remains an is-
sue. In oral peripheral nerve blocks, Shurtz et al. found no
significant difference in onset of action, depth of blockade,
or pain of injection between buffered and nonbuffered ar-
ticaine (41). With bupivacaine in oral nerve blocks, Shya-
mala et al. observed significantly decreased onset of ac-
tion and pain of injection with the addition of sodium bi-
carbonate, with no differences in duration of action (42).
Other studies showed no significant effect on duration
or onset of action with the addition of sodium bicarbon-
ate to peripheral nerve blocks, such as with lidocaine in
brachial plexus blocks and with bupivacaine in lumbar
plexus blocks (43, 44). Capogna et al. observed signifi-
cantly shorter onset of action with alkalinized lidocaine
and bupivacaine for epidural blocks, alkalinized lidocaine
for brachial plexus block, and alkalinized mepivacaine for
sciatic and femoral nerve blocks, suggesting that the site
of peripheral nerve block may play a role in these inconsis-
tencies (45).
It is difficult to determine the utility of sodium bicar-
bonate as an adjuvant to peripheral nerve blocks due to
conflicting results in studies. Theoretically, sodium bicar-
bonate could be an effective adjuvant in select peripheral
nerve blocks, but more studies may be necessary to fully
determine its potential. In addition, current statistically
significant findings show decreased onset of action only,
but the clinical significance of this is unclear (46). Shya-
mala et al. observed that the addition of bicarbonate short-
ened local anesthetic onset of action by one minute, and
Tetzlaff et al. observed that sodium bicarbonate shortened
the mean onset of action from 2.7 minutes to 1.0 minute
(42, 47). These observed differences in onset of action are
likely not clinically significant in the perioperative setting,
as peripheral nerve blocks are often performed before the
patient is taken to the operating room, making a differ-
ence of one to two minutes inconsequential (39). Further-
more, the addition of sodium bicarbonate to local anes-
thetics has not been approved for clinical use, so its use in
this role should be performed with caution (13).
3. Clinical Studies: Safety and Efficacy
A prospective, randomized, double-blind study looked
at the addition of neostigmine to enhance an axillary
brachial plexus nerve block where 34 participants were as-
signed to 2 groups (29). The treatment group was given
500 µg of neostigmine (1 mL) plus 500 mg of mepiva-
caine (50 mL), while the control group was given 500
mg of mepivacaine (50 mL) plus saline (0.9%, 1 mL).(48)
The study found no difference between the two groups
in the time the block took effect and the total duration
of the block. However, there was a lower reported pain
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rating on a visual analog scale (VAS: 14.7 ± 9.9 vs. 32.4
± 23.5; P < 0.05) in the neostigmine plus mepivacaine
group 24 hours post-surgery (48). In addition, this group
required fewer additional analgesics in the first 24 hours
post-surgery (P < 0.05) possibly due to the long duration
of anti-inflammatory effects. While there were no reported
side effects and all cardiovascular functions remained sta-
ble with the addition of neostigmine, the sample size of
this study was small. The authors concluded that neostig-
mine was an effective adjuvant anesthetic at relieving post-
operative pain with axillary brachial plexus blocks (29).
Another study examined the combined effect of
hyaluronidase and lidocaine with epinephrine during
inferior alveolar nerve blocks (IAN) (48). This prospective,
double-blinded study randomized 30 participants into
two groups that received an IAN block at two appoint-
ments that were at least one week apart. One group was
assigned 24 mg buffered lidocaine plus 12 µg epinephrine
into a 1.2 mL volume of solution. The second group was
assigned 24 mg buffered lidocaine plus 12 µg epinephrine
into a 1.8 mL volume of solution that was buffered with
0.33 mEq/mL of sodium bicarbonate with the addition
of hyaluronidase solution (150 USP units) (48). The ad-
dition of hyaluronidase did not improve the number
of participants who experienced anesthetic success (P <
0.05). Nor did it improve participant’s discomfort ratings
as measured on a 0 to 3 scale (P < 0.05) but in fact, the
lidocaine with hyaluronidase group had an increase in
postoperative pain (P < 0.05) than compared to the lido-
caine plus epinephrine group. The researchers concluded
that hyaluronidase should not be added to anesthetic
during an IAN block as there was no additional benefit and
a potential to harm healthy tissue (48). Another prospec-
tive, double-blinded study that looked at an IAN block
examined buffered versus non-buffered lidocaine with
epinephrine in patients with symptomatic irreversible
pulpitis (48). There was no significant difference in the
success of the block as measured by having no or mild pain
on a VAS between one group that received 2% lidocaine
with 1: 80,000 epinephrine buffered with 8.4% sodium
bicarbonate and a second group that received only 2% lido-
caine with 1: 80,000 epinephrine (buffered group: 62.5%;
non-buffered group: 47.5%; P > 0.05) (49). The same author
completed another prospective, randomized, double-
blinded study to examine if the same buffered solution
was effective as a buccal infiltration during an IAN also in
patients with symptomatic irreversible pulpitis (50). One
hundred patients were placed into the same two groups
as above with a successful block measured as having no or
mild pain on a VAS. There was a statistically higher success
rate using the buffered solution using a buccal infiltration
(buffered group: 78%; non-buffered group: 44%; P < 0.05)
(50).
Dexmedetomidine is a highly selective alpha-2 ago-
nist, and has been used as an adjuvant to local anesthet-
ics in many central and peripheral nerve blocks (51-57). An-
other study looked at adding either dexmedetomidine or
epinephrine to 1% mepivacaine during a brachial plexus
block (58). Thirty patients aged 18 - 65 years were ran-
domly assigned to 3 groups; one group was given 40 mL of
1% mepivacaine as a control, the second group was given
40 mL of 1% mepivacaine plus an adjuvant of 200 µg of
epinephrine, and the third group was given 40 mL of 1%
mepivacaine plus an adjuvant of 1 µg/kg of dexmedeto-
midine. Both groups that had an adjuvant drug added to
the anesthetic showed an increase in motor block duration
(min) (epinephrine: 334.3 ± 46.5, dexmedetomidine: 349
± 28.2; P < 0.05) and an increase in sensory block duration
(min) (epinephrine: 353.5 ± 53.4, dexmedetomidine: 367.9
± 35.8; P < 0.05) with no statistical difference between
the two adjuvant groups (58). There was also an increased
time when first onset of pain, measured in minutes, was
felt as compared to the control group (epinephrine: 349.3
± 50.5, dexmedetomidine: 358.0 ± 36.2; P < 0.05), how-
ever, there was no difference between the three groups
in onset time to complete block or to mean VAS for the
first sensation of pain (P < 0.05) (58). There was a differ-
ence in participants affected heart rate as the mepivacaine
plus epinephrine group had an increase in heart rate com-
pared to baseline at 10 to 40 min post drug administration
(P < 0.05), while the mepivacaine plus dexmedetomidine
group had a decrease in heart rate compared to the group
with epinephrine at 20 to 40 min (P < 0.05) (58).
Another study evaluated the addition of clonidine at
two different potency levels compared to tramadol during
a brachial plexus block (59). Ninety patients were random-
ized with a single-blind investigation into three groups;
one group received lidocaine plus 1 µg/kg clonidine, the
second group received lidocaine plus a larger dose of 1.5
µg/kg clonidine, and a third group received lidocaine plus
1 mg/kg tramadol. The time to rescue analgesia (min) was
significantly shorter with tramadol as an adjuvant as com-
pared to both groups of clonidine and between the two
groups of clonidine (tramadol: 313.3 ± 21.4; 1 µg clonidine:
470.7 ± 38.6; 1.5 µg clonidine: 491.8 ± 33.9; P < 0.001) (59).
A significantly faster onset to sensory block (seconds) was
seen with both groups of clonidine as compared to tra-
madol (tramadol: 293.6 ± 19.1; 1 µg clonidine: 259.0 ± 39;
1.5 µg clonidine: 241.0 ± 4.3; P < 0.001) and a significantly
faster onset to motor block (s) (tramadol: 674.0 ± 180.8; 1
µg clonidine: 462.0 ± 83.6; 1.5 µg clonidine: 396.0 ± 0.2; P
< 0.001) (59). When the mean duration of sensory and mo-
tor blockade (min) was compared, there was a statistically
longer duration between both groups of clonidine and tra-
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madol but not between the 2 groups of clonidine (sensory
tramadol: 247.2 ± 25.2; 1 µg clonidine: 301.3 ± 34; 1.5 µg
clonidine: 315.7± 6.9; P < 0.001) (motor tramadol: 186.0±
20; 1 µg clonidine: 237.0 ± 18.2; 1.5 µg clonidine: 235.0 ±
2.4; P < 0.001). Both groups with clonidine as an adjuvant
remained hemodynamically stable with no major side ef-
fects reported. There was additionally less nausea reported
with the adjuvant use of clonidine than with tramadol (59).
Another study looked into epinephrine as an adjuvant
in digital nerve blocks. This study looked at the use of bupi-
vacaine versus lidocaine with epinephrine in digital nerve
blocks to compare pain at the injection site, time of onset,
and duration of the block. Twelve patients were random-
ized in this prospective, double-blinded study into two
groups. One group received 1% lidocaine with epinephrine,
versus the other group received 0.5% bupivacaine. There
was no difference between the median time onset of anes-
thetic between the two groups (lidocaine + epi: 3.45 min (3
- 8); bupivacaine: 3.30 min (3 - 8); P = 0.84). However, the li-
docaine plus epinephrine group did have significantly less
pain at the site of anesthetic injection as measured by a 0
- 100mm VAS (median 26.00 mm (4-52) vs. 40.50 mm (10 -
71); P < 0.05). This group also showed a shorter duration
of anesthetic (lidocaine + epi: 321 min (228 - 463); bupiva-
caine: 701 min (24 - 913); P < 0.05) which the authors con-
cluded should still be sufficient to allow the use of lido-
caine plus epinephrine use in an emergency room (60).
The effect of epinephrine on potentially affecting per-
fusion and blood flow was assessed in a randomized
controlled trial of supraclavicular brachial plexus blocks.
Eighty-two patients were placed in 2 groups where one
group received 12.5 mL of 2% lidocaine, 12.5 mL of 0.75%
ropivacaine, and 0.1 mL of normal saline in the non-
epinephrine group while the other group received 12.5 mL
of 2% lidocaine, 12.5 mL of 0.75% ropivacaine, and 5mcg/mL
of epinephrine in the epinephrine group. Using a pulse
oximeter to assess the perfusion index, the study found the
addition of epinephrine did not affect the perfusion index
or perfusion index ratio during the block (P = 0.894 and P
= 0.079, respectively) (61). All clinical studies are summa-
rized below in Table 1.
3.1. Ketamine as Adjunct to Nerve Block
A three-arm, randomized control trial was conducted
to observe effects of mixing ketamine with local anesthet-
ics during ACL reconstruction. The study utilized 87 pa-
tients undergoing ACL reconstruction, all with similar de-
mographics and surgery duration. Patients were random-
ized into three groups which received either a single per-
ineural 40 mL dose of 0.375% ropivacaine, a 40 mL dose
of ketamine 40 mg and 0.375% ropivacaine mixture, or a
40 mL dose of 0.375% ropivacaine preoperatively in addi-
tion to 40 mg of ketamine intravenously during the opera-
tion. Anesthesiologists and patients were blinded to group
allocation. Efficacy was assessed using AUC scores based
on pain scores from a numerical rating scale at rest and
with movement, which was assessed from 4 hours to 48
hours postoperatively. The study also included duration of
the sensory block, time to first request for pain medicine,
and time to full motor block to find significant differences.
No significance was found between the three groups for
time to motor block, but the group with the mixture of
ketamine and ropivacaine displayed significance reduced
post-op pain, more time to first request for analgesics, and
longer sensory block. IV-administered ketamine during
operation did not produce the same effects as preoperative
administration (62).
A case series was published describing the effects of ke-
tamine on three patients with complex regional pain syn-
drome (CRPS) after gunshot wounds. Patients ranged from
28 - 45 years old and exhibited typical allodynia of CRPS
Type II and vicarious pain. Patients first received tradi-
tional treatments including pharmacological treatments
for nerve pain or satellite ganglion blocks such as bupi-
vacaine with lidocaine, clonidine, or morphine. Patients
used a VAS to report temporary relief of their pain, but no
lasting relief of other symptoms such as heat allodynia and
vicarious symptoms. Patients were then treated with nerve
blocks using ketamine as an adjunct with a treatment regi-
men of 0.5 mg/kg/day. All three patients reported dramatic
and lasting relief of all symptoms after this treatment (18).
Another double-blinded clinical trial was conducted to
observe the effects of ketamine versus fentanyl as an ad-
junct to lidocaine for axillary nerve block in 60 patients un-
dergoing upper extremity surgery for fractures. Patients
were divided into equal groups to receive either a 1% lido-
caine and 50 microgram fentanyl or 1% lidocaine with 30
mg ketamine. Study measures were duration of analgesia
after operation, time to first request for pain medication,
and amount of pain medicine received over 24 hours. This
study found a significant difference in the severity of pain
and that there was an increased time to first request for
analgesics for the group who received fentanyl as opposed
to ketamine. The study concluded that fentanyl may be a
better adjunct for axillary nerve block than ketamine but
did note that it would be beneficial for higher doses of ke-
tamine to be used in future trials (63).
4. Conclusions
Local anesthetics are often limited in their motor and
sensory block durations and the potential for negative side
effects in the cardiac and central nervous systems. Some
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Table 1. Clinical Efficacy and Safety - Adjuvant Drugs for Peripheral Nerve Blocks
Author (y) Groups Studied and Interventions Results and Findings Conclusions
Bone et al. (1999) (29) Patients between 18 to 75 y of age, ASA I
or II scheduled for an elective upper
extremity surgery with an axillary
plexus block. Exclusion criteria included
the use of analgesics 24 hrs before
surgery, pregnancy, history of asthma or
arrhythmias, and allergy to anesthesia.
No difference between the two groups in
the onset for nerve block and the total
duration of the block. Lower reported
pain rating on a visual analog scale (VAS:
14.7 ± 9.9 vs. 32.4 ± 23.5; P < .05) in the
neostigmine plus mepivacaine group 24
hours post-surgery and they required
less additional analgesics in the first 24
hours post-surgery (P < 0.05).
Neostigmine was an effective adjuvant
anesthetic at relieving postoperative
pain with axillary brachial plexus blocks.
Ridenour et al. (2001) (48) Healthy subjects not taking medications
that alter pain perception. Teeth were
free of caries, periodontal disease, large
restorations, or trauma.
No improvement in anesthetic success
(P < 0.05) with hyaluronidase. lidocaine
with hyaluronidase group had an
increase in postoperative pain (P <
0.05).
Hyaluronidase should not be added to
anesthetic during an IAN block.
Saatchi et al. (2015) (49) Healthy patients over 18 with active pain
in a mandibular posterior tooth.
Exclusion criteria included significant
medical conditions, allergies to local
anesthetics, active areas of disease at the
injection site, or taking medications to
affect anesthetic assessment.
Was no significant difference in
anesthetic success between group using
sodium bicarbonate buffered lidocaine
with epinephrine vs. non-buffered
lidocaine with epinephrine (P > 0.05).
The success of an IAN block in
mandibular molars with irreversible
pulpitis was not improved with
buffering a lidocaine with epi solution
with sodium bicarbonate.
Saatchi et al. (2016) (50) Healthy patients over 18 with active
moderate to severe pain in vital
mandibular first molar.
Statistically higher success rate using
the sodium bicarbonate buffered
lidocaine with epinephrine solution vs.
non buffered lidocaine with
epinephrine using a buccal infiltration
(P < 0.05).
The efficacy of an IAN block in
mandibular first molars with
irreversible pulpitis was improved with
sodium bicarbonate buccal infiltration.
Song et al. (2014) (58) Patients 18 - 65 years of age, ASA I or II
scheduled for upper extremity surgery
and brachial plexus block. Exclusion
criteria included BMI > 35, pregnancy,
liver or kidney disorder, diabetic
neuropathy, arrythmia, or α-2
adrenergic drug within 2 weeks.
Increase in motor and sensory block
duration and an increased time when
first onset of pain with epinephrine and
dexmedetomidine (P < 0.05). No
difference in onset time to complete
block as compared to mepivacaine (P <
0.05).
Duration of block and post-op control of
pain with dexmedetomidine is similar
to epinephrine.
Kelika et al. (2017) (59) Patients 18 - 50 years of age, ASA I or II
with routine or emergency forearm and
hand surgery, surgery performed under
tourniquet. Patients with
cardiovascular, respiratory, CNS, liver, or
kidney disease and bleeding disorders
were excluded.
Increase in sensory, and motor onset as
well increased duration of sensory and
motor block, and longer time until
rescue analgesic needed with both
groups of clonidine as compared to
tramadol (P < 0.001).
Clonidine provides a quicker onset and
longer-lasting level of a brachial plexus
block.
Alhelail et al. (2009) (60) Patients over 18 years of age without a hx
of cardiovascular, liver, diabetes,
peripheral vascular disease, or hand
conditions.
Less pain at the injection site and shorter
duration of anesthetic seen in lidocaine
plus epinephrine group (P < 0.05).
Lidocaine plus epinephrine was
sufficient to use for emergency room
procedures.
Kim et al. (2020) (61) Patients between 19 and 76 years of age
ASA I or II with unilateral upper
extremity surgery.
There was no significant difference in
the perfusion index or ratio when using
epinephrine as an adjuvant drug (P =
0.894 and P = 0.079, respectively).
The PI and PI ratio were not affected with
the use of epinephrine.
Zhu et al. (2020) (62) Patients aged 25 - 45, ASA I or II
undergoing elective ACL repair.
No difference in onset of motor block
between groups. Decreased post op
pain, longer onset for rescue analgesic,
and longer duration of sensory block see
in ketamine and ropivacaine group.
Ketamine given preoperatively
improved patient satisfaction and
patients experienced less postoperative
pain.
Sunder et al. (2008) (18) 3 case reports of patients aged 28 - 45
years old with gunshot wounds with
CRPS Type II.
Dramatic and long-lasting relief of heat
allodynia seen with ketamine.
Ketamine impact on central pain
pathway showed positive response on
heat allodynia symptoms.
Akhondzadeh et al. (2019) (63) Patients aged 18 to 75 years of age, ASA I
or II undergoing upper extremity
surgery due to fracture.
The fentanyl group showed less pain 9,
12, and 24 hours post-surgery compared
to ketamine group.
Fentanyl may be a better adjuvant for
axillary blocks compared to ketamine.
adjuvant drugs have been well studied to recommend use
in various environments such as perioperative, acute, or
chronic use setting with no reported adverse side effects.
The use of adjuvants such as NMDA antagonists, neostig-
mine, epinephrine, and sodium bicarbonate have shown
safety and efficacy in increasing the duration of a periph-
eral nerve block, increasing the onset of action, improving
pain post-op with need for rescue analgesics, or limiting
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the required needed dose. However, more research should
go into showing the efficacy of these adjuvants for nerve
block prolongation as studies have been either mixed or
have small sample sizes.
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